Page 50 - Recursion Pharmaceuticals News Today

JCMR recently Announced Artificial Intelligence for Healthcare Applications study with 200+ market data Tables and Figures spread through Pages and ea

Zavain Dar, Lux Capital Altitude Lab, a healthcare and life sciences incubator founded in 2020 by Recursion and The University of Utahs PIVOT Center, fills the critical role of attracting and supporting underrepresented entrepreneurs. The incubator focuses on developing diverse and inclusive businesses to innovate lower cost, higher quality, and more accessible healthcare solutions. Altitude Labs first cohort includes nine minority or women founders, who are tackling everything from personalize...

  JCMR recently Announced Artificial Intelligence for Healthcare Applications study with 200+ market data Tables and Figures spread through Pages

Aging is characterized by a progression in the loss of integrity and physiological functions over time. Epigenetics of aging refers to changes in gene

BioPharma

Share this article Share this article SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurren...

/PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological...

Ask A Fund Manager: Platinum Asset Management's Dr Bianca Ogden picks 2 medical stocks still under the radar, plus 2 well-known ones to hold.

Viswa Colluru Viswa is CEO of Enveda Biosciences. He founded Enveda after leading cross-functional teams across innovation, product strategy, and translational biology as an early employee at Recursion Pharmaceuticals. He holds a Ph.D. in immuno-oncology from the University of Wisconsin-Madison, where he developed new therapeutic agents for the treatment of prostate cancer. At Enveda, he leads a world-class team of machine learning scientists and drug hunters engaged in unlocking the potential ...

LendingTree Inc (NASDAQ:TREE) worth about $18.6 million as of the stock’s Friday’s close. Two of the New York-based investment firm’s flagship funds made the trade. The Ark Fintech Innovation ETF (NYSE:ARKF) bought 23,470 shares, representing 0.12% of the ETF, and the ARK Next Generation Internet ETF (NYSE:ARKW) bought 58,600 shares, representing 0.19% of the ETF. The Ark Genomic Revolution ETF (BATS:ARKG) bought 78,639 shares of Ionis Pharmaceutical Co (NYSE:IONS), estimated to be ab...